NIH SBIR — Receipt (First Post-Reauthorization
Supports United States. small businesses moving vision innovation from feasibility to development.
The NIH Small Business Innovation Research (SBIR) program funds commercially oriented biomedical and health technology R&D by US small businesses across the full NIH portfolio and partner agencies CDC and FDA. The program was reauthorized on April 13, 2026 following a lapse; as of May 2026, NIH has no active SBIR Notice of Funding Opportunity. The next standard receipt date is September 5, 2026, a…
Small business commercialization of biomedical and health technology innovations across all NIH Institutes and Centers, with Phase I feasibility awards up to approximately $314,000 and Phase II awards up to approximately $2.1 million.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline